AKT1 and cardiac hypertrophy: On the other hand, aortic banding determined a significant increase in phospho-Akt levels twelve weeks after development of hypertrophy compared to controls both in placebo groups (1.1±0.9 vs. 2.8±0.3, SHAM vs. LVH, p<0.01) and in valsartan groups (1.7±1.1 vs. 4.4±0.6, SHAM+VAL vs. LVH+VAL, p<0.01).